ALZ-801
ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation for Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved pharmacokinetic properties and gastrointestinal tolerability.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | ALZ-801 |
|---|---|
| Iupac 化学名称 | (S)-3-(2-Amino-3-methylbutanamido)propane-1-sulfonic acid |
| 同义词 | ALZ-801; ALZ801; ALZ 801; BLU8499; BLU 8499; BLU-8499; NRM8499; NRM 8499; NRM-8499 |
| 英文同义词 | ALZ-801; ALZ801; ALZ 801; BLU8499; BLU 8499; BLU-8499; NRM8499; NRM 8499; NRM-8499 |
| 分子式 | C8H18N2O4S |
| 分子量 | 238.30 |
| Smile | O=S(CCCNC([C@@H](N)C(C)C)=O)(O)=O |
| InChiKey | NRZRFNYKMSAZBI-ZETCQYMHSA-N |
| InChi | InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1 |
| Cas号 | 1034190-08-3 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018 Aug 3. doi: 10.1007/s40263-018-0554-0. [Epub ahead of print] PubMed PMID: 30076539.
2: Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26. PubMed PMID: 29182706.
3: Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. doi: 10.1007/s40262-017-0608-3. PubMed PMID: 29063518; PubMed Central PMCID: PMC5814546.
4: Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z. PubMed PMID: 28435985; PubMed Central PMCID: PMC5488121.
